Date:_	2023.11	. 20						
Your N	ame:	Luqing Han						
Manus	cript Title:	Expression and signi	ficance of serum	KL-6 in patient	s with acute res	piratory d	listress sync	drome
Manus	cript numb	er (if known):						

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	<u>√</u> None	
4	Consulting fees	<u>√</u> None	

5	Payment or honoraria for	<u>√</u> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>√</u> None	
	testimony		
7	Support for attending meetings and/or travel	<u>√</u> _None	
8	Patents planned, issued or	<u>√</u> None	
	pending		
9	Participation on a Data	<u>√</u> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>√</u> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	/ None	
11	Stock of Stock options	<u>√</u> None	
12	Receipt of equipment,	√ None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	√ None	
	financial interests		
Dlaa	an aumanarian tha abaun an	afiat of interest in the falle.	uing how

The author declared no potential conflicts of interest with respect to the research, author- ship, and publication of this article.	f

Please place an "X" next to the following statement to indicate your agreement:

Date:_	2023	. 11. 20									
Your N	lame:	Shuai	Wang								
Manus	cript Ti	tle:Expressi	on and signi	ficance of seru	m KL-6 in	patients v	with acu	te respira	tory dist	tress syr	ndrome
Manus	script n	umber (if kn	own):								

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
	AH		planning of the work
1	All support for the present	<u>√</u> None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	√ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>√</u> None	
4	Consulting fees	<u>√</u> None	

5	Payment or honoraria for	<u>√</u> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>√</u> None	
	testimony		
7	Support for attending meetings and/or travel	<u>√</u> _None	
8	Patents planned, issued or	<u>√</u> None	
	pending		
9	Participation on a Data	<u>√</u> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>√</u> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	/ None	
11	Stock of Stock options	<u>√</u> None	
12	Receipt of equipment,	√ None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	√ None	
	financial interests		
Dlaa	an aumanarian tha abaun an	afiat of interest in the falle.	uing how

The author declared no potential conflicts of interest with respect to the research, author- ship, and publication of this article.	f

Please place an "X" next to the following statement to indicate your agreement:

Date: 20	3. 11. 20
Your Name	Jialin Ma
Manuscrip	Title:Expression and significance of serum KL-6 in patients with acute respiratory distress syndrome
Manuscrip	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	<u>√</u> None	
4	Consulting fees	<u>√</u> None	

5	Payment or honoraria for	<u>√</u> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>√</u> None	
	testimony		
7	Support for attending meetings and/or travel	<u>√</u> _None	
8	Patents planned, issued or	<u>√</u> None	
	pending		
9	Participation on a Data	<u>√</u> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>√</u> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	/ None	
11	Stock of Stock options	<u>√</u> None	
12	Receipt of equipment,	√ None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	√ None	
	financial interests		
Dlaa	an aumanarian tha abaun an	afiat of interest in the falle.	uing how

The author declared no potential conflicts of interest with respect to the research, author- ship, and publication of this article.	f

Please place an "X" next to the following statement to indicate your agreement:

Date:_	2023.1	1.20						
Your N	ame:	Zhongyan Zhao						
Manus	cript Title	Expression and sign	ificance of serum	KL-6 in patient	s with acute re	spiratory d	istress synd	rome
Manus	cript num	ber (if known):						

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	<u>√</u> None	
4	Consulting fees	<u>√</u> None	

5	Payment or honoraria for	<u>√</u> None				
	lectures, presentations,					
	speakers bureaus,					
	manuscript writing or					
	educational events					
6	Payment for expert	<u>√</u> None				
	testimony					
7	Support for attending meetings and/or travel	<u>√</u> _None				
8	Patents planned, issued or	<u>√</u> None				
	pending					
9	Participation on a Data	<u>√</u> None				
	Safety Monitoring Board or					
	Advisory Board					
10	Leadership or fiduciary role	<u>√</u> None				
	in other board, society,					
	committee or advocacy					
11	group, paid or unpaid	/ Name				
11	Stock or stock options	<u>√</u> None				
12	Descipt of aguinment	/ Name				
12	Receipt of equipment, materials, drugs, medical	<u>√</u> None				
	writing, gifts or other					
	services					
13	Other financial or non-	<u>√</u> None				
	financial interests					
		·				
Dlaa	Disease summering the phase conflict of interest in the following boys					

The author declared no potential conflicts of interest with respect to the research, author- ship, and publication of this article.				

Please place an "X" next to the following statement to indicate your agreement: